Cancer drug developer Thar Pharmaceuticals adds to series A
Thar Pharmaceuticals has added a $250,000 investment to its series A round as the cancer drug developer looks to continue clinical trials, according to a regulatory document. Pittsburgh, Pennsylvania-based Thar is aiming for a series A round of up to $9.6 million, CEO Ray Houck said in January. Houck didn’t respond to an inquiry last […]